President Trump's threat of pharmaceutical tariffs has been softened by a new drug-pricing deal with Pfizer. The agreement includes a three-year exemption from tariffs for Pfizer in exchange for $70 billion in domestic investments. This signals a potential path for other drugmakers to strike similar deals, securing immunity from levies and shifting policy away from punitive tariffs. The administration intends to pursue these agreements before imposing tariffs, with Eli Lilly expected to be next. Drugmaker stocks saw an increase following the announcement, reflecting industry relief.

Prepared by Christopher Adams and reviewed by editorial team.